News

Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model

  • Data featured in oral presentation and poster session at 48 th European Cystic Fibrosis Conference
    06/06/2025

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

  • SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination Sionna plans to advance SION-719 to a Phase 2a proof-of-concept add-on to standard of care trial in cystic fibrosis patients, and SION-451 to a Phase 1 healthy volunteer dual combination trial Next trials to initiate in the second half of 2025 with topline data expected in mid-2026 Sionna to hold a conference call today at 8:00 a.m. ET WALTHAM, Mass.
    06/04/2025
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Sionna Therapeutics, Inc. (SION) can sell. Click on Rating Page for detail.

The price of Sionna Therapeutics, Inc. (SION) is 17.35 and it was updated on 2025-06-30 13:00:19.

Currently Sionna Therapeutics, Inc. (SION) is in undervalued.

News
    
News

Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

  • WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Healthcare Conference in Miami, Florida on Wednesday, June 11th 2025 at 8:00 a.m.
    Tue, Jun. 03, 2025

Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference

  • WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that preclinical data assessing combinations of Sionna's nucleotide-binding domain 1 (NBD1) stabilizers, SION-451 and SION-719, with complementary Sionna CFTR modulators, galicaftor (SION-2222) and SION-109, will be featured in an oral presentation at the European Cystic Fibrosis Society's (ECFS) 48th European Cystic Fibrosis Conference, being held June 4-7, 2025 in Milan, Italy.
    Thu, May. 22, 2025

Sionna Therapeutics Reports First Quarter 2025 Financial Results

  • Phase 1 dosing completed for NBD1 stabilizers SION-719 & SION-451; both compounds continue to be generally well tolerated Phase 1 topline data anticipated this quarter On track to initiate Phase 2a proof-of-concept trial and at least one dual combination MAD trial in the second half of 2025; topline data for both anticipated in mid-2026 Strong cash position following completed upsized IPO, with approximately $354.7 million in cash and cash equivalents, expected to fund operations into 2028 WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today reported financial results for the quarter ended March 31, 2025, and provided a business update.
    Mon, May. 12, 2025

Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025

  • WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at The Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 12:30 p.m. ET.
    Wed, Apr. 30, 2025

Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

  • Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline data anticipated in first half of 2025
    Thu, Mar. 20, 2025
SEC Filings
SEC Filings

Sionna Therapeutics, Inc. (SION) - SCHEDULE 13G

  • SEC Filings
  • 06/16/2025

Sionna Therapeutics, Inc. (SION) - 4

  • SEC Filings
  • 06/16/2025

Sionna Therapeutics, Inc. (SION) - 8-K - Current report

  • SEC Filings
  • 06/13/2025

Sionna Therapeutics, Inc. (SION) - 8-K - Current report

  • SEC Filings
  • 06/04/2025

Sionna Therapeutics, Inc. (SION) - 8-K - Current report

  • SEC Filings
  • 05/12/2025

Sionna Therapeutics, Inc. (SION) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/12/2025

Sionna Therapeutics, Inc. (SION) - DEFA14A

  • SEC Filings
  • 04/29/2025

Sionna Therapeutics, Inc. (SION) - DEF 14A

  • SEC Filings
  • 04/29/2025

Sionna Therapeutics, Inc. (SION) - ARS

  • SEC Filings
  • 04/29/2025

Sionna Therapeutics, Inc. (SION) - 3

  • SEC Filings
  • 04/01/2025

Sionna Therapeutics, Inc. (SION) - 8-K - Current report

  • SEC Filings
  • 03/20/2025

Sionna Therapeutics, Inc. (SION) - 10-K - Current report

  • SEC Filings
  • 03/20/2025

Sionna Therapeutics, Inc. (SION) - SCHEDULE 13D

  • SEC Filings
  • 02/18/2025

Sionna Therapeutics, Inc. (SION) - SCHEDULE 13G

  • SEC Filings
  • 02/14/2025

Sionna Therapeutics, Inc. (SION) - SCHEDULE 13D

  • SEC Filings
  • 02/13/2025

Sionna Therapeutics, Inc. (SION) - 4

  • SEC Filings
  • 02/12/2025

Sionna Therapeutics, Inc. (SION) - 8-K - Current report

  • SEC Filings
  • 02/10/2025

Sionna Therapeutics, Inc. (SION) - 4

  • SEC Filings
  • 02/10/2025

Sionna Therapeutics, Inc. (SION) - EFFECT

  • SEC Filings
  • 02/07/2025

Sionna Therapeutics, Inc. (SION) - S-8

  • SEC Filings
  • 02/07/2025

Sionna Therapeutics, Inc. (SION) - 424B4

  • SEC Filings
  • 02/07/2025

Sionna Therapeutics, Inc. (SION) - SEC STAFF LETTER

  • SEC Filings
  • 02/06/2025

Sionna Therapeutics, Inc. (SION) - S-1MEF

  • SEC Filings
  • 02/06/2025

Sionna Therapeutics, Inc. (SION) - CERT

  • SEC Filings
  • 02/06/2025

Sionna Therapeutics, Inc. (SION) - 3

  • SEC Filings
  • 02/06/2025

Sionna Therapeutics, Inc. (SION) - CORRESP

  • SEC Filings
  • 02/04/2025

Sionna Therapeutics, Inc. (SION) - 8-A12B

  • SEC Filings
  • 02/04/2025

Sionna Therapeutics, Inc. (SION) - S-1/A

  • SEC Filings
  • 02/03/2025

Sionna Therapeutics, Inc. (SION) - CORRESP

  • SEC Filings
  • 01/24/2025

Sionna Therapeutics, Inc. (SION) - S-1

  • SEC Filings
  • 01/17/2025

Sionna Therapeutics, Inc. (SION) - CORRESP

  • SEC Filings
  • 01/17/2025

Sionna Therapeutics, Inc. (SION) - UPLOAD

  • SEC Filings
  • 12/10/2024

Sionna Therapeutics, Inc. (SION) - DRSLTR

  • SEC Filings
  • 11/26/2024

Sionna Therapeutics, Inc. (SION) - DRS/A

  • SEC Filings
  • 11/26/2024

Sionna Therapeutics, Inc. (SION) - UPLOAD

  • SEC Filings
  • 10/10/2024

Sionna Therapeutics, Inc. (SION) - SEC STAFF LETTER

  • SEC Filings
  • 10/10/2024

Sionna Therapeutics, Inc. (SION) - DRS

  • SEC Filings
  • 09/12/2024
More Headlines
News

Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference

  • BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at the 45th Annual TD Cowen Health Care Conference on Monday, March 3, 2025 at 3:10 p.m. ET.
  • 02/24/2025

Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

  • BOSTON, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the closing of its upsized initial public offering of 12,176,467 shares of its common stock at a public offering price of $18.00 per share, which includes 1,588,234 shares issued upon the full exercise by the underwriters of their option to purchase additional shares of common stock in the offering. All of the shares of common stock were sold by Sionna.
  • 02/10/2025

U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week

  • Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Four small Asia-based issuers also went public in the US - EPWK Holdings, FBS Global, Plutus Financial Group, and Huachen AI Parking Management Technology. Eight IPOs are currently scheduled to list in the week ahead, although some small issuers may also join the calendar throughout the week.
  • 02/08/2025

Sionna Therapeutics Prices Upsized Initial Public Offering

  • BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the pricing of its upsized initial public offering of 10,588,233 shares of its common stock at a public offering price of $18.00 per share. In addition, Sionna has granted the underwriters a 30-day option to purchase up to 1,588,234 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. Sionna's shares are scheduled to begin trading on the Nasdaq Global Market on February 7, 2025 under the ticker symbol "SION." The offering is expected to close on February 10, 2025, subject to the satisfaction of customary closing conditions. All shares of common stock are being offered by Sionna.
  • 02/06/2025

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

  • Five IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Four microcaps submitted initial filings this week - Vistek, Awaysis Capital, QMSK Technology, and TV Channels Network. Two IPOs are currently scheduled for the week ahead, and a few more sizable names are eligible to launch.
  • 02/01/2025

Sionna Therapeutics Seeks $100 Million in IPO For Cystic Fibrosis Treatments

  • Sionna Therapeutics aims to raise $100 million in an IPO to advance its cystic fibrosis drug candidates, currently in Phase 1 and Phase 2 trials. The firm is well-capitalized with $137.5 million in cash and backed by top-tier life science venture capital firms. The cystic fibrosis therapeutics market is projected to grow at a 14.2% CAGR, reaching $22.8 billion by 2030, offering significant market potential.
  • 01/24/2025
Unlock
SION Ratings Summary
SION Quant Ranking